CIK 0001549595
- Large accelerated filer
Nurix Therapeutics, Inc.
Sign in to watch- Ticker
- NRIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Nov 30
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 270838048
- Phone
- +1 415-660-5320
- Business address
- 1600 SIERRA POINT PKWY, BRISBANE, CA, 94005
- Former names
- Nurix, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,712,859
- in 10 filings, $1.0M under 10b5-1 plans
Net −$1,712,859. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 1 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-04-12 | Beaurang Pierre Chief Business Officer | Exercise or conversion · Employee Stock Option (right to buy) | −2,396 | 0 | ||
| 2021-04-12 | Beaurang Pierre Chief Business Officer | Exercise or conversion · Employee Stock Option (right to buy) | −5,104 | 36,562 | ||
| 2021-04-05 | Hansen Gwenn Chief Scientific Officer | Exercise or conversion | +400 | $7.26 | $3K | 14,204 |
| 2021-04-05 | Hansen Gwenn Chief Scientific Officer | Sale | −400 | $35.00 | $14K | 13,804 |
| 2021-04-05 | Hansen Gwenn Chief Scientific Officer | Exercise or conversion · Employee Stock Option (right to buy) | −400 | 73,466 | ||
| 2021-04-01 | Hansen Gwenn Chief Scientific Officer | Exercise or conversion | +400 | $7.26 | $3K | 14,204 |
| 2021-04-01 | Hansen Gwenn Chief Scientific Officer | Sale | −400 | $31.55 | $13K | 13,804 |
| 2021-04-01 | Hansen Gwenn Chief Scientific Officer | Exercise or conversion · Employee Stock Option (right to buy) | −400 | 73,866 | ||
| 2021-03-25 | Beaurang Pierre Chief Business Officer | Exercise or conversion | +4,330 | $0.84 | $4K | 4,330 |
| 2021-03-25 | Beaurang Pierre Chief Business Officer | Exercise or conversion · Employee Stock Option (right to buy) | −4,330 | 2,396 | ||
| 2021-03-16 | Hansen Gwenn Chief Scientific Officer | Exercise or conversion | +800 | $7.26 | $6K | 14,604 |
| 2021-03-16 | Hansen Gwenn Chief Scientific Officer | Sale | −800 | $45.00 | $36K | 13,804 |
| 2021-03-16 | Hansen Gwenn Chief Scientific Officer | Exercise or conversion · Employee Stock Option (right to buy) | −800 | 74,266 | ||
| 2021-03-10 | Ring Christine General Counsel | Exercise or conversion | +2,000 | $1.86 | $4K | 2,805 |
| 2021-03-10 | Ring Christine General Counsel | Sale | −900 | $39.44 | $35K | 1,905 |
| 2021-03-10 | Ring Christine General Counsel | Sale | −300 | $41.13 | $12K | 1,605 |
| 2021-03-10 | Ring Christine General Counsel | Sale | −405 | $42.67 | $17K | 1,200 |
| 2021-03-10 | Ring Christine General Counsel | Sale | −395 | $44.11 | $17K | 805 |
| 2021-03-10 | Ring Christine General Counsel | Exercise or conversion · Employee Stock Option (right to buy) | −2,000 | 117,666 | ||
| 2021-03-08 | Beaurang Pierre Chief Business Officer | Exercise or conversion | +7,500 | $0.84 | $6K | 7,500 |
Page 37 of 42 · 829 trades